Microengineered Bioartificial Liver Chip for Drug Toxicity Screening
Source abstract
Abstract
Abstract Microfluidic 3D cell culture is a promising technology for the screening of drug toxicity profiles. In this study, a bioartificial liver consisting of a surface‐engineered microfluidic silicon chip with microtrenches mimicking hepatic sinusoids is shown to extend 3D primary hepatocyte culture and improve in vitro drug screening for hepatotoxicity, with respect to the state‐of‐the‐art literature on this subject. Primary hepatocytes hosted in the 3D heparin‐coated microtrenches (the bioartificial liver) secrete high levels of albumin and urea over 4 weeks. The cytotoxicity of common drugs, namely, acetaminophen, chlorpromazine, and tacrine, was assessed on primary hepatocytes both at day 1 and day 7. The results suggest that mimicking hepatic sinusoids using a microtrench format allows the maintenance of difficult‐to‐culture primary hepatocytes to be extended to 4 weeks and provides an alternative model to animal studies for the screening of the cytotoxicity of new drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Liver physiology and pathology · Innovative Microfluidic and Catalytic Techniques Innovation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Future Industries Institute University of South Australia Mawson Lakes SA 5095 Australia
Manufacturing, Commonwealth Scientific and Industrial Research Organisation (CSIRO) Clayton VIC 3168 Australia
Monash Institute of Pharmaceutical Sciences Monash University Parkville VIC 3052 Australia
Department of Information Engineering University of Pisa via G. Caruso 16 56122 Pisa Italy
References (37)
Show source-provided references
1. 10.1016/j.jprot.2016.01.01610.1016/j.jprot.2016.01.016 ↗
2. Chhabra R. · Int. J. Clin. Biomed. Res. · 2015 · 2 · 65
3. 10.1172/JCI6996610.1172/JCI69966 ↗
4. 10.1001/jama.287.17.221510.1001/jama.287.17.2215 ↗
5. 10.1039/c0ib00119h10.1039/c0ib00119h ↗
6. 10.1038/nrd175010.1038/nrd1750 ↗
7. 10.1006/rtph.2000.139910.1006/rtph.2000.1399 ↗
8. 10.1021/acs.chemrestox.5b0046510.1021/acs.chemrestox.5b00465 ↗
9. 10.1080/0360253060109348910.1080/03602530601093489 ↗
10. 10.1289/ehp.9810651110.1289/ehp.98106511 ↗
11. 10.4103/0976-500X.8593210.4103/0976-500X.85932 ↗
12. Bolt H. · EXCLI J. · 2013 · 12 · 1027
13. 10.1089/adt.2014.57310.1089/adt.2014.573 ↗
14. 10.1016/j.jsps.2013.11.00210.1016/j.jsps.2013.11.002 ↗
15. Caldwell G. W. · Curr. Opin. Drug Discovery Dev. · 2000 · 3 · 30
16. 10.1089/adt.2010.036510.1089/adt.2010.0365 ↗
17. 10.1039/b900912d10.1039/b900912d ↗
18. 10.1002/bit.2310410.1002/bit.23104 ↗
19. 10.1186/scrt37710.1186/scrt377 ↗
20. 10.1038/nature0505810.1038/nature05058 ↗
21. 10.1038/nbt136110.1038/nbt1361 ↗
22. Weng Y.‐S. · Adv. Mater. · 2017 · 29 · 17011545
23. 10.1002/bit.2046310.1002/bit.20463 ↗
24. 10.1002/adfm.20129003610.1002/adfm.201290036 ↗
25. 10.1016/j.biomaterials.2010.01.06810.1016/j.biomaterials.2010.01.068 ↗
26. 10.1021/la801140u10.1021/la801140u ↗
27. 10.1021/acs.chemrestox.6b0015010.1021/acs.chemrestox.6b00150 ↗
28. 10.1016/j.eurpolymj.2014.12.03310.1016/j.eurpolymj.2014.12.033 ↗
29. 10.1023/B:BMMD.0000048560.96140.ca10.1023/B:BMMD.0000048560.96140.ca ↗
30. 10.1186/1475-925X-11-9310.1186/1475-925X-11-93 ↗
31. 10.1002/bit.2565910.1002/bit.25659 ↗
32. 10.1038/ctg.2016.1310.1038/ctg.2016.13 ↗
33. 10.1007/s00204-013-1080-y10.1007/s00204-013-1080-y ↗
34. 10.1177/02611929990270060910.1177/026119299902700609 ↗
35. 10.1211/002235702179210.1211/0022357021792 ↗
36. 10.1021/jm00402a00210.1021/jm00402a002 ↗
37. 10.1016/0041-008X(70)90034-710.1016/0041-008X(70)90034-7 ↗